CT
Caldera is a clinical‑stage biotechnology company developing a bispecific antibody, CLD‑423, for inflammatory bowel disease and related immune‑mediated disorders. The drug simultaneously targets the IL‑23p19 and TL1A pathways to achieve higher efficacy and safety than single‑target therapies. Caldera is advancing CLD‑423 through Phase 1 trials and intends to commercialize the product via partnerships or licensing agreements.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Caldera is a clinical-stage biotechnology company developing novel therapeutics for inflammatory bowel disease (IBD). The company is advancing CLD-423, a first-in-class bispecific antibody targeting the IL-23p19 and TL1A pathways. This approach aims to deliver optimized efficacy and safety profiles for patients with IBD and other immunologic diseases.